What is it about?
Why do promising cancer treatments sometimes fail to deliver lasting benefits? Our review connects the biology of chemotherapy resistance with the clinical experience of developing new treatments. We examine how the tumor microenvironment, cellular signaling, and epigenetic changes reinforce resistance and how nanotechnology, gene therapy, and combination treatments could address these processes. Alongside these mechanisms, we examine clinical trials, terminated or withdrawn studies, and withdrawn oncology drugs or indications. We discuss reported setbacks involving efficacy, safety, recruitment, funding, and development priorities. This brings therapeutic opportunities and the practical lessons of clinical development into one discussion.
Featured Image
Photo by RephiLe water on Unsplash
Why is it important?
The review helps readers connect proposed treatments with the evidence and obstacles encountered during clinical development. It emphasizes the necessity of predictive biomarkers, better delivery, representative experimental models, and rigorous clinical evaluation. A central discussion concerns how molecular explanations of resistance relate to broad clinical outcomes such as insufficient benefit. Understanding that relationship requires evidence; a failed trial or withdrawn indication alone does not establish resistance as its cause.
Perspectives
For me, an important part of this review is giving clinical setbacks the attention they deserve. When discussing an emerging treatment, I want readers to ask both what makes it promising and what we can learn from earlier attempts. I hope that the paper serves as a useful reference for researchers planning experiments, clinicians following therapeutic development, and readers evaluating new cancer-treatment strategies. I would welcome discussion on one question in particular: how can we design studies that explain why a treatment fails, as well as whether it works?
Dr. Prashant Sharma
Read the Original
This page is a summary of: Transforming tumor microenvironments: nanotechnology and gene therapy in cellular signaling and epigenetic insight into chemo-resistance, Journal of Experimental & Clinical Cancer Research, May 2026, Springer Science + Business Media,
DOI: 10.1186/s13046-026-03720-8.
You can read the full text:
Contributors
The following have contributed to this page
